
Heartflow, Inc.
93
Recent developments include Q3 2026 earnings reporting a net loss but revenue growth, ongoing market education efforts, and continued clinical validation supporting product adoption.
- Heartflow reported a net loss for Q3 2026 but showed revenue growth, reflecting ongoing investments in market expansion and product development [N3].
- The company’s Q3 2026 earnings call highlighted progress in expanding payor coverage and market education for Heartflow Plaque Analysis and other products [N1][N2].
- Clinical validation and guideline support continue to underpin the Heartflow Platform’s adoption in the CAD diagnostic pathway [N2].
- Liquidity remains strong with a current ratio of 4.41 and cash plus short-term investments totaling approximately $168 million as of September 30, 2026 [S2].
Heartflow, Inc. develops and commercializes AI-driven software solutions to improve the diagnosis and management of coronary artery disease (CAD). Its flagship Heartflow Platform enhances coronary computed tomography angiography (CCTA) by creating personalized 3D models of patients' coronary arteries to assess blood flow, stenosis, and plaque characteristics. The platform's products include Heartflow RoadMap Analysis, Heartflow FFR CT Analysis, Heartflow Plaque Analysis, and upcoming tools such as Heartflow PCI Navigator and Plaque Tracker. The technology is clinically validated through multiple trials and supported by major cardiovascular guidelines. The company operates a cloud-based platform integrated into physician workflows, enabling scalable, timely, and accurate diagnostics. Heartflow's products have dedicated reimbursement codes and broad payer coverage in the US. As of late 2025, the platform had been used in over 600,000 patients, with a growing installed base of accounts. The company reported a net loss in Q3 2026 but maintains strong liquidity.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Heartflow, Inc. offers an AI-powered platform for non-invasive diagnosis and management of coronary artery disease, leveraging advanced computational fluid dynamics and deep learning applied to CCTA scans. The platform includes multiple products with clinical guideline support and reimbursement coverage. As of Q3 2026, the company reported a net loss of $11.5 million and maintains strong liquidity with a current ratio of 4.41. Recent earnings commentary highlights revenue growth alongside widening losses and ongoing market expansion efforts.
Heartflow's platform addresses a significant unmet need in CAD diagnosis by providing more accurate, non-invasive, and clinically actionable insights than traditional methods. The company's extensive clinical validation, guideline support, and reimbursement coverage underpin adoption. The growing installed base and expanding product portfolio, including upcoming tools like PCI Navigator and Plaque Tracker, offer potential to deepen clinical utility and market penetration. The large proprietary dataset and AI-driven continuous improvement may sustain technological leadership and enhance workflow efficiencies, supporting long-term growth in a large cardiovascular disease market.
Heartflow operates in a competitive and evolving medical technology landscape where adoption depends on physician acceptance, reimbursement policies, and regulatory approvals. The company has reported net losses and may face challenges in achieving sustained profitability. Market penetration could be constrained by the need for continued clinical validation, payor coverage expansion, and integration into diverse healthcare systems. Technological advances by competitors or changes in clinical guidelines could impact Heartflow's market position. Additionally, reliance on a cloud-based platform requires robust data security and compliance with healthcare regulations.
Heartflow's competitive advantage stems from its proprietary AI-powered platform that integrates advanced computational fluid dynamics with deep learning to deliver personalized, clinically validated diagnostics for CAD. The extensive dataset of over 160 million annotated CCTA images accumulated over a decade supports continuous algorithm refinement and product improvement. The platform's integration into physician workflows, combined with dedicated reimbursement codes and guideline endorsements from leading cardiovascular societies, creates high barriers to entry. Additionally, the platform's ability to reduce unnecessary invasive procedures and improve clinical and economic outcomes strengthens customer loyalty and retention.
• Regulatory and Reimbursement Risk: Changes in regulatory approvals or reimbursement policies could affect product adoption and revenue.
• Clinical Adoption Risk: Physician acceptance and integration into clinical workflows are critical for sustained growth.
• Competitive Risk: Emerging technologies or competitors could erode Heartflow's market share or technological advantage.
• Financial Risk: The company has reported net losses and must manage expenses and capital to support operations and growth.
• Data Security and Compliance Risk: Operating a cloud-based platform requires maintaining stringent data security and compliance with healthcare regulations.
Business trends: Continued adoption of AI-powered non-invasive CAD diagnostics supported by clinical validation and guideline endorsements.
Execution milestones: Expansion of product portfolio with PCI Navigator and Plaque Tracker; broadening payor coverage and market education.
Key risks: Regulatory and reimbursement changes, clinical adoption challenges, competitive pressures, and financial sustainability.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Heartflow, Inc. provides AI-powered software designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease (CAD) using the Heartflow Platform, which analyzes coronary computed tomography angiography (CCTA) scans to create personalized 3D heart models (S1).
- The Heartflow Platform delivers insights on blood flow, stenosis, plaque volume, and plaque composition, improving diagnostic accuracy beyond traditional non-invasive imaging (S1).
- As of December 31, 2025, the Heartflow Platform has been used to assess CAD in over 600,000 patients, including 219,000 in 2025 (S1).
- The platform includes multiple products: Heartflow RoadMap Analysis, Heartflow FFR CT Analysis (flagship product), Heartflow Plaque Analysis, and upcoming Heartflow PCI Navigator and Plaque Tracker (S1).
- Heartflow FFR CT Analysis provides a 3D anatomical reconstruction calculating fractional flow reserve (FFR) values to identify clinically significant CAD and guide intervention decisions; it represented 98% of total revenue as of end 2025 (S1).
- Heartflow Plaque Analysis offers automated, AI-driven 3D plaque assessment, validated against invasive IVUS, and influences medical management decisions beyond CCTA alone (S1).
- The Heartflow Platform is supported by clinical guidelines from the American Heart Association and American College of Cardiology, with CCTA as Class 1, Level A and Heartflow FFR CT Analysis as Class 2a, Level B for CAD diagnosis (S1).
- Heartflow FFR CT Analysis and Plaque Analysis have dedicated CPT reimbursement codes effective January 1, 2024 and 2026 respectively, with broad coverage across US payers (S1).
- The platform integrates into physician workflows via cloud-based technology and bi-directional data sharing, enabling continuous algorithm improvement and workflow efficiencies (S1).
- The company reported a net loss of $11.5 million and basic/diluted EPS of -$0.13 for the quarter ended September 30, 2026, with cash and equivalents of $31.6 million and short-term investments of $136.1 million, yielding a current ratio of 4.41 and cash ratio of 3.14 as of that date (S2).
- Recent earnings calls and reports indicate revenue growth alongside widening losses, with ongoing efforts to expand market education and payor coverage for newer products (N1, N2, N3, N8).
- The company has demonstrated clinical validation through multiple trials (PRECISE, NXT, PACIFIC) and maintains a large annotated image database exceeding 160 million images to refine AI models (S1).
- Heartflow's products aim to reduce unnecessary invasive procedures and improve catheterization lab efficiency, enhancing patient and provider experience by streamlining diagnosis and reducing radiation exposure compared to nuclear imaging (S1).
Generated 2026-11-15
- N1
- N2
- S1 | 2026-03-18 | 10-K
- S2 | 2026-11-12 | 10-Q
- N1 | 2026-11-13 | www.nasdaq.com | HeartFlow (HTFL) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/heartflow-htfl-q3-2026-earnings-call-transcript
- N2 | 2026-11-13 | www.nasdaq.com | What Heartflow (HTFL) Said on Its Q3 Earnings Call | https://www.nasdaq.com/articles/what-heartflow-htfl-said-its-q3-earnings-call
- N3 | 2026-11-12 | www.nasdaq.com | HeartFlow (HTFL) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/heartflow-htfl-reports-q3-loss-beats-revenue-estimates
- N4 | 2026-11-06 | www.nasdaq.com | iRhythm Holdings, Inc. (IRTC) Q3 Earnings Surpass Estimates | https://www.nasdaq.com/articles/irhythm-holdings-inc-irtc-q3-earnings-surpass-estimates
- N5 | 2026-10-27 | www.nasdaq.com | Pulmonx Corporation (LUNG) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/pulmonx-corporation-lung-reports-q3-loss-tops-revenue-estimates
- N6 | 2026-10-06 | www.nasdaq.com | Biotech Stocks At 52-Week Highs - PCVX +31% On Phase 3 Results, INFU, ILMN +7%, CRL+7%, HTFL +5% | https://www.nasdaq.com/articles/biotech-stocks-52-week-highs-pcvx-31-phase-3-results-infu-ilmn-7-crl7-htfl-5
- N7 | 2026-09-09 | www.nasdaq.com | UBS Initiates Coverage of HeartFlow at Neutral | https://www.nasdaq.com/articles/ubs-initiates-coverage-heartflow-neutral
- N8 | 2026-08-17 | www.nasdaq.com | Heartflow Q2 Loss Widens Despite 48% Jump In Revenue, Lifts FY26 Outlook | https://www.nasdaq.com/articles/heartflow-q2-loss-widens-despite-48-jump-revenue-lifts-fy26-outlook
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


